Racial differences and geographic variations in oral anticoagulation treatment among Medicare patients with non-valvular atrial fibrillation.
<h4>Introduction</h4>Use of oral anticoagulants (OACs) for stroke reduction in atrial fibrillation (AF) varies by race and geography within the United States. We seek to better understand the relationship between OAC underutilization, race, and US geography.<h4>Methods</h4>Pa...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2024-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0314345 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846099008669351936 |
|---|---|
| author | Larry R Jackson Amiee Kang Virginia Noxon Nipun Atreja Dionne M Hines Melissa Hagan Jenny Jiang Brett D Atwater |
| author_facet | Larry R Jackson Amiee Kang Virginia Noxon Nipun Atreja Dionne M Hines Melissa Hagan Jenny Jiang Brett D Atwater |
| author_sort | Larry R Jackson |
| collection | DOAJ |
| description | <h4>Introduction</h4>Use of oral anticoagulants (OACs) for stroke reduction in atrial fibrillation (AF) varies by race and geography within the United States. We seek to better understand the relationship between OAC underutilization, race, and US geography.<h4>Methods</h4>Patients with AF were selected from the US Centers for Medicare & Medicaid Services claims database from January 1, 2013, to December 31, 2016. The final population consisted of patients with 12 months of health plan enrollment before and after their index AF diagnosis, with a baseline CHAD2S2-VASc ≥2 and of either Black or White race (other races are underrepresented in the data). Among those with AF that met the inclusion criteria, patients who were prescribed warfarin or DOACs within 12 months after the index date were extracted. Each patient was assigned to a US county based on their 5-digit zip code and OAC use was stratified by race. Statistically significant differences were determined by student's t-test and chi-square.<h4>Results</h4>Of the 2,390,830 final patients, 94.1% were White and 5.9% were Black patients. Mean (SD) age and HASBLED scores were 78 (9) and 3.9 (1.2) respectively, for Black patients and 80 (9) and 3.3 (1.2), respectively, for White patients (p<0.0001). The mean (SD) CHAD2S2-VASc scores were 4.5 (1.9) for White patients, and 5.3 (1.9) for Black patients with p<0.0001, respectively. Black patients (vs White patients) had a higher non-treatment (no DOAC or warfarin) rate (56.1% vs 47.4%, p<0.0001) across the US which was particularly notable in the southeast. In addition, treatment rates were highly variable within each US state. Counties with dense population more frequently demonstrated significant differences by race than counties with sparse population.<h4>Conclusion</h4>Our study showed differences in the use of OACs across US counties and among various racial groups. These disparities highlighted the areas of unmet need for both Black and White patients. |
| format | Article |
| id | doaj-art-67637bab8c5b4759ac9da185c3a2217c |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-67637bab8c5b4759ac9da185c3a2217c2025-01-01T05:31:06ZengPublic Library of Science (PLoS)PLoS ONE1932-62032024-01-011912e031434510.1371/journal.pone.0314345Racial differences and geographic variations in oral anticoagulation treatment among Medicare patients with non-valvular atrial fibrillation.Larry R JacksonAmiee KangVirginia NoxonNipun AtrejaDionne M HinesMelissa HaganJenny JiangBrett D Atwater<h4>Introduction</h4>Use of oral anticoagulants (OACs) for stroke reduction in atrial fibrillation (AF) varies by race and geography within the United States. We seek to better understand the relationship between OAC underutilization, race, and US geography.<h4>Methods</h4>Patients with AF were selected from the US Centers for Medicare & Medicaid Services claims database from January 1, 2013, to December 31, 2016. The final population consisted of patients with 12 months of health plan enrollment before and after their index AF diagnosis, with a baseline CHAD2S2-VASc ≥2 and of either Black or White race (other races are underrepresented in the data). Among those with AF that met the inclusion criteria, patients who were prescribed warfarin or DOACs within 12 months after the index date were extracted. Each patient was assigned to a US county based on their 5-digit zip code and OAC use was stratified by race. Statistically significant differences were determined by student's t-test and chi-square.<h4>Results</h4>Of the 2,390,830 final patients, 94.1% were White and 5.9% were Black patients. Mean (SD) age and HASBLED scores were 78 (9) and 3.9 (1.2) respectively, for Black patients and 80 (9) and 3.3 (1.2), respectively, for White patients (p<0.0001). The mean (SD) CHAD2S2-VASc scores were 4.5 (1.9) for White patients, and 5.3 (1.9) for Black patients with p<0.0001, respectively. Black patients (vs White patients) had a higher non-treatment (no DOAC or warfarin) rate (56.1% vs 47.4%, p<0.0001) across the US which was particularly notable in the southeast. In addition, treatment rates were highly variable within each US state. Counties with dense population more frequently demonstrated significant differences by race than counties with sparse population.<h4>Conclusion</h4>Our study showed differences in the use of OACs across US counties and among various racial groups. These disparities highlighted the areas of unmet need for both Black and White patients.https://doi.org/10.1371/journal.pone.0314345 |
| spellingShingle | Larry R Jackson Amiee Kang Virginia Noxon Nipun Atreja Dionne M Hines Melissa Hagan Jenny Jiang Brett D Atwater Racial differences and geographic variations in oral anticoagulation treatment among Medicare patients with non-valvular atrial fibrillation. PLoS ONE |
| title | Racial differences and geographic variations in oral anticoagulation treatment among Medicare patients with non-valvular atrial fibrillation. |
| title_full | Racial differences and geographic variations in oral anticoagulation treatment among Medicare patients with non-valvular atrial fibrillation. |
| title_fullStr | Racial differences and geographic variations in oral anticoagulation treatment among Medicare patients with non-valvular atrial fibrillation. |
| title_full_unstemmed | Racial differences and geographic variations in oral anticoagulation treatment among Medicare patients with non-valvular atrial fibrillation. |
| title_short | Racial differences and geographic variations in oral anticoagulation treatment among Medicare patients with non-valvular atrial fibrillation. |
| title_sort | racial differences and geographic variations in oral anticoagulation treatment among medicare patients with non valvular atrial fibrillation |
| url | https://doi.org/10.1371/journal.pone.0314345 |
| work_keys_str_mv | AT larryrjackson racialdifferencesandgeographicvariationsinoralanticoagulationtreatmentamongmedicarepatientswithnonvalvularatrialfibrillation AT amieekang racialdifferencesandgeographicvariationsinoralanticoagulationtreatmentamongmedicarepatientswithnonvalvularatrialfibrillation AT virginianoxon racialdifferencesandgeographicvariationsinoralanticoagulationtreatmentamongmedicarepatientswithnonvalvularatrialfibrillation AT nipunatreja racialdifferencesandgeographicvariationsinoralanticoagulationtreatmentamongmedicarepatientswithnonvalvularatrialfibrillation AT dionnemhines racialdifferencesandgeographicvariationsinoralanticoagulationtreatmentamongmedicarepatientswithnonvalvularatrialfibrillation AT melissahagan racialdifferencesandgeographicvariationsinoralanticoagulationtreatmentamongmedicarepatientswithnonvalvularatrialfibrillation AT jennyjiang racialdifferencesandgeographicvariationsinoralanticoagulationtreatmentamongmedicarepatientswithnonvalvularatrialfibrillation AT brettdatwater racialdifferencesandgeographicvariationsinoralanticoagulationtreatmentamongmedicarepatientswithnonvalvularatrialfibrillation |